| Auranofin inhibition of thioredoxin reductase sensitizes lung neuroendocrine tumor cells (NETs) and small cell lung cancer (SCLC) cells to sorafenib as well as inhibiting SCLC … SS Johnson, D Liu, JT Ewald, C Robles-Planells, C Pulliam, ... Cancer biology & therapy 25 (1), 2382524, 2024 | | 2024 |
| Targeting CXCR4 with [212Pb/203Pb]-Pentixather Significantly Increases Overall Survival in Small Cell Lung Cancer KA Christensen, MA Fath, JT Ewald, C Robles-Planells, SA Graves, ... bioRxiv, 2024.09. 06.611663, 2024 | | 2024 |
| Chemokine Receptor CXCR4 Radioligand Targeted Therapy Using 177Lutetium-pentixather for Pulmonary Neuroendocrine Cancers MA Fath, D Liu, JT Ewald, C Robles-Planells, AM Tomanek-Chalkley, ... Radiation research 201 (1), 35-47, 2024 | 3 | 2024 |
| Auranofin Inhibition of Thioredoxin Reductase in a Preclinical Model of Small Cell Lung Cancer. SS Johnson, D Liu, JT Ewald, C Robles-Planells, K Bayanbold, BR Wels, ... Biorxiv: the Preprint Server for Biology, 2023 | 1 | 2023 |
| Establishment of novel neuroendocrine carcinoma patient-derived xenograft models for receptor peptide-targeted therapy CG Tran, LC Borbon, JL Mudd, E Abusada, S AghaAmiri, SC Ghosh, ... Cancers 14 (8), 1910, 2022 | 11 | 2022 |
| Comparison of drug sensitivity profiles of various NEN spheroids CG Tran, LC Borbon, SK Sherman, G Li, J Mudd, E Abusada, ... PANCREAS 51 (3), E35-E35, 2022 | | 2022 |
| Pre-Clinical Evaluation of Alpha-Particle Radiotherapy Targeting CXCR4 in Small Cell Lung Cancer D Liu, J Ewald, M Fath, S Johnson, M Schultz, D Spitz, Y Menda, ... PANCREAS 51 (3), E35-E35, 2022 | | 2022 |
| A Phase II Trial to Evaluate the Safety and Dosimetry of [Lu-177] Lu-DOTA-TATE in Adolescent Patients With Somatostatin Receptor (SSTR)-Positive Gastroenteropancreatic … MS O'Dorisio, M Gaze, C Sabado, F Brouri, I Folitar PANCREAS 51 (3), E59-E59, 2022 | | 2022 |
| Safety and efficacy of peptide-receptor radionuclide therapy in elderly neuroendocrine tumor patients D Theiler, M Cattaneo, LO Dierickx, P Igaz, S Grozinsky-Glasberg, ... Cancers 13 (24), 6290, 2021 | 7 | 2021 |
| Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase … JH Pollard, Y Menda, KD Zamba, M Madsen, MS O'Dorisio, T O'Dorisio, ... Cancer biotherapy & radiopharmaceuticals 36 (8), 632-641, 2021 | 15 | 2021 |
| 1122TiP A phase II trial to evaluate the safety and dosimetry of [177Lu] Lu-DOTA-TATE in adolescent patients with somatostatin receptor (SSTR)-positive gastroenteropancreatic … MN Gaze, MS O'Dorisio, C Sábado, F Brouri, I Folitar Annals of Oncology 32, S920, 2021 | | 2021 |
| Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for personalized treatment of selected patients with neuroendocrine tumors DL Bushnell, KL Bodeker, TM O’Dorisio, MT Madsen, Y Menda, S Graves, ... Journal of Nuclear Medicine 62 (9), 1274-1277, 2021 | 13 | 2021 |
| Prospective analysis of the impact of 68Ga-DOTATOC positron emission tomography–computerized axial tomography on management of pancreatic and small bowel neuroendocrine tumors SN Ghobrial, Y Menda, GK Zamba, SL Mott, K Gaimari-Varner, D Dick, ... Pancreas 49 (8), 1033-1036, 2020 | 8 | 2020 |
| Radioligand theranostics in the management of neuroendocrine tumors AG Harris, AI Vinik, TM O'Dorisio, MS O'Dorisio Pancreas 49 (5), 599-603, 2020 | 2 | 2020 |
| Evolution of neuroendocrine tumor therapy TM O’Dorisio, AG Harris, MS O’Dorisio Surgical Oncology Clinics 29 (2), 145-163, 2020 | 13 | 2020 |
| Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma D Liu, M Fath, RCJ Planells, EW Balk, AM Bellizzi, DR Spitz, MS O'Dorisio NEUROENDOCRINOLOGY 110, 14-14, 2020 | | 2020 |
| 569 Immunohistochemistry for the Biotheranostic Markers SSTR2A and CXCR4 in Pheochromocytoma/Paraganglioma S Boukhar, J Howe, T O'Dorisio, MS O'Dorisio, A Bellizzi | | 2020 |
| Preclinical evaluation of chemokine receptor 4 (CXCR4) as a theranostic target in high-risk neuroblastoma D Liu, M Schultz, M Li, D Lee, K Nourmahnad, A Bellizzi, MS O'Dorisio JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS 62, S518-S519, 2019 | | 2019 |
| Preclinical Evaluation of Chemokine Receptor 4 Antagonists for High Grade NETs and NECs Theranostics D Liu, M Li, D Lee, K Nourmahnad, NJ Baumhover, MK Schultz, ... PANCREAS 48 (3), 444-444, 2019 | | 2019 |
| Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma A Jha, K De Luna, CA Balili, C Millo, CA Paraiso, A Ling, MK Gonzales, ... Frontiers in Oncology 9, 53, 2019 | 50 | 2019 |
